GaviLyte - C

Manufacturer
Lupin Pharmaceuticals,Inc. | Novel Laboratories, Inc.
Effective date
2025-09-10
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
4
Source
full-release
Hydrated at
2026-05-31 21:42:35

Label at a glance#

ProductGaviLyte - C TM
Active ingredientPOLYETHYLENE GLYCOL 3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM SULFATE ANHYDROUS
Label structure10 sections

Indications and uses

GaviLyte- C with flavor pack is indicated for bowel cleansing prior to colonoscopy or barium enema X-ray examination.

Dosage and administration

GaviLyte- C with flavor pack can be administered orally or by nasogastric tube. Patients should fast at least 3 hours prior to administration. A one hour waiting period after the appearance of clear liquid stool should be allowed prior to examination to complete bowel evacuation. No foods except clear liquids should be permitted prior to examination after GaviLyte- C with flavor pack administration. ORAL: The reco...

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

GaviLyte- C with flavor pack is a white, colon lavage preparation provided as water-soluble components for solution. In solution this preparation with lemon flavor pack added delivers the following, in grams per liter.

Polyethylene glycol 3350        240.00

Sodium chloride                      5.84

Potassium chloride                  6.72

Sodium bicarbonate                2.98

Sodium sulfate                        22.72

Flavor ingredients                   0.500

When dissolved in sufficient water to make 4 liters, the final solution contains 125 mEq/L sodium, 10 mEq/L potassium, 20 mEq/L bicarbonate, 80 mEq/L sulfate, 35 mEq/L chloride and 18 mEq/L polyethylene glycol 3350. The reconstituted solution is an isosmotic solution, for oral administration, having mild salty taste. This preparation can be used without the lemon flavor pack and is administered orally or via nasogastric tube.

Each lemon flavor pack (2 g) contains natural lemon flavor powder, saccharin sodium, maltodextrin.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

GaviLyte- C with flavor pack cleanses the bowel by induction of diarrhea. The osmotic activity of polyethylene glycol 3350, in combination with the electrolyte concentration, results in virtually no net absorption or excretion of ions or water. Accordingly, large volumes may be administered without significant changes in fluid and electrolyte balance.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

GaviLyte- C with flavor pack is indicated for bowel cleansing prior to colonoscopy or barium enema X-ray examination.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

GaviLyte- C with flavor pack is contraindicated in patients known to be hypersensitive to any of the components. GaviLyte- C with flavor pack is contraindicated in patients with ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis or toxic megacolon.

WARNINGS

WARNINGS SECTION

Flavor pack is for use only in combination with the contents of the accompanying 4 liter container. No other additional ingredients (e.g., flavorings) should be added to the solution. GaviLyte- C with flavor pack should be used with caution in patients with severe ulcerative colitis.

PRECAUTIONS

PRECAUTIONS SECTION

General

Patients with impaired gag reflex, unconscious or semiconscious patients and patients prone to regurgitation or aspiration should be observed during the administration of GaviLyte- C with flavor pack, especially if it is administered via nasogastric tube.

If gastrointestinal obstruction or perforation is suspected appropriate studies should be performed to rule out these conditions before administration of GaviLyte- C with flavor pack.

 INFORMATION FOR PATIENTS

GaviLyte- C with flavor pack produces a watery stool which cleanses the bowel prior to examination.

For best results, no solid food should be ingested during the 3 to 4 hour period prior to the initiation of GaviLyte- C with flavor pack administration. In no case should solid foods be eaten within 2 hours of drinking GaviLyte- C with flavor pack. The rate of administration is 240 mL (8 fl. oz.) every 10 minutes. Rapid drinking of each portion is preferred rather than drinking small amounts continuously. The first bowel movement should occur approximately one hour after the start of GaviLyte- C with flavor pack administration.

Administration of GaviLyte- C with flavor pack should be continued until the watery stool is clear and free of solid matter. This normally requires the consumption of approximately 3 to 4 liters (3 to 4 quarts), although more or less may be required in some patients. The unused portion should be discarded.

DRUG INTERACTIONS

Oral medication administered within one hour of start of administration of GaviLyte- C with flavor pack may be flushed from the gastrointestinal tract and not absorbed.

CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY

Studies to evaluate carcinogenic or mutagenic potential or potential to adversely affect male or female fertility have not been performed.

PREGNANCY

Category C. Animal reproduction studies have not been conducted with GaviLyte- C with flavor pack, and it is not known whether GaviLyte- C with flavor pack can affect reproductive capacity or harm the fetus when administered to a pregnant patient. GaviLyte- C with flavor pack should be given to a pregnant patient only if clearly needed.

PEDIATRIC USE

Safety and effectiveness in pediatric patients have not been established.

GERIATRIC USE

Published literature contains isolated reports of serious adverse reactions following the administration of PEG-ELS products in patients over 60 years of age. These adverse events include upper GI bleeding from Mallory-Weiss Tear, esophageal perforation, asystole, sudden dyspnea with pulmonary edema, and "butterfly-like" infiltrate on chest x-ray after vomiting and aspirating PEG.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Nausea, abdominal fullness and bloating are the most frequent adverse reactions, occurring in up to 50% of patients. Abdominal cramps, vomiting and anal irritation occur less frequently. These adverse reactions are transient. Isolated cases of urticaria, rhinorrhea, dermatitis, and rarely anaphylaxis, angioedema, tongue edema, and face edema have been reported which may represent allergic reactions.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

GaviLyte- C with flavor pack can be administered orally or by nasogastric tube. Patients should fast at least 3 hours prior to administration. A one hour waiting period after the appearance of clear liquid stool should be allowed prior to examination to complete bowel evacuation. No foods except clear liquids should be permitted prior to examination after GaviLyte- C with flavor pack administration.

ORAL: The recommended adult oral dose is 240 mL (8 fl. oz.) every 10 minutes (see INFORMATION FOR PATIENTS). Lavage is complete when fecal discharge is clear. Lavage is usually complete after the ingestion of 3 to 4 liters.

NASOGASTRIC TUBE: GaviLyte- C with flavor pack is administered at a rate of 20 to 30 mL per minute (1.2 to 1.8 L/hour).

PREPARATION OF GaviLyte- C with flavor pack SOLUTION: This preparation can be used with or without the lemon flavor pack.

1. To add flavor, tear open lemon flavor pack at the indicated marking and pour contents into the bottle BEFORE reconstitution.

2. SHAKE WELL to incorporate flavoring into the powder.

3. Add tap water to FILL line. Replace cap tightly and mix or shake well until all ingredients have dissolved. (No other additional ingredients, e.g. flavorings, should be added to the solution.)

Note: If not using flavor pack, omit steps one and two, above.

HOW SUPPLIED

HOW SUPPLIED SECTION

GaviLyte- C with flavor pack is supplied in 4 liter bottles with an attached lemon flavor pack. Each 4 liter bottle contains polyethylene glycol-3350 240 g, sodium chloride 5.84 g, potassium chloride 2.98 g, sodium bicarbonate 6.72 g, sodium sulfate (anhydrous) 22.72 g. This preparation is supplied in powdered form, for oral administration as a solution.

GaviLyte- C with flavor pack 4liter: NDC 43386-060-19

Store at 20° to 25°C (68° to 77°F): excursions permitted between 15° to 30°C (59° to 86°F).

KEEP RECONSTITUTED SOLUTION REFRIGERATED. USE WITHIN 48 HOURS. DISCARD UNUSED PORTION.

LUPIN and the HOW SUPPLIEDHOW SUPPLIED are registered trademarks of Lupin Pharmaceuticals, Inc.

Manufactured by:

Novel Laboratories, Inc.

Somerset, NJ 08873, USA

Manufactured for:

Lupin Pharmaceuticals, Inc.

Naples FL, 34108

SAP Code: 278922

Rev. 11/2024

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Gavilyte-C with Flavor Pack (PEG-3350 (240g) and electrolytes for oral solution, USP) with flavor pack

Label
Label

Lemon Flavor Pack

lemon flavor
lemon flavor

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
967023Gavilyte-C Powder for Oral SolutionPSN4
966914polyethylene glycol 3350 240 GM / potassium chloride 2.98 GM / sodium bicarbonate 6.74 GM / sodium chloride 5.86 GM / sodium sulfate 227.41 GM Powder for Oral SolutionPSN4
967023polyethylene glycol 3350 240000 MG / potassium chloride 2980 MG / sodium bicarbonate 6720 MG / sodium chloride 5840 MG / sodium sulfate 22720 MG Powder for Oral Solution [GaviLyte-C]SBD4
966914polyethylene glycol 3350 240000 MG / potassium chloride 2980 MG / sodium bicarbonate 6720 MG / sodium chloride 5840 MG / sodium sulfate 22720 MG Powder for Oral SolutionSCD4
967023Gavilyte-C (PEG-3350 240 GM / KCl 2.98 GM / NaCl 5.84 GM / NaHCO3 6.72 GM / Na2SO4 22.72 GM) Powder for 4 L Oral SolutionSY4
967023Gavilyte-C (polyethylene glycol 3350 240 GM / potassium chloride 2.98 GM / sodium bicarbonate 6.72 GM / sodium chloride 5.84 GM / sodium sulfate 22.72 GM) Powder for Oral SolutionSY4
966914polyethylene glycol 3350 240 GM / potassium chloride 2.98 GM / sodium bicarbonate 6.74 GM / sodium chloride 5.86 GM / sodium sulfate 227.41 GM Powder for Oral SolutionSY4
966914POLYETHYLENE GLYCOL 3350 240000 MG / K+ Chloride 2980 MG / NaHCO3 6720 MG / NaCl 5840 MG / sodium sulfate 22720 MG Powder for Oral SolutionSY4
967023POLYETHYLENE GLYCOL 3350 240000 MG / K+ Chloride 2980 MG / NaHCO3 6720 MG / NaCl 5840 MG / sodium sulfate 22720 MG Powder for Oral Solution [GaviLyte-C]SY4
966914POLYETHYLENE GLYCOL 3350 240000 MG / Pot Chloride 2980 MG / NaHCO3 6720 MG / NaCl 5840 MG / sodium sulfate 22720 MG Powder for Oral SolutionSY4
967023POLYETHYLENE GLYCOL 3350 240000 MG / Pot Chloride 2980 MG / NaHCO3 6720 MG / NaCl 5840 MG / sodium sulfate 22720 MG Powder for Oral Solution [GaviLyte-C]SY4

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
POLYETHYLENE GLYCOL 3350 Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813
POTASSIUM CATION Pharmacologic Class Indexing3Indexing - Pharmacologic Class20180813
SODIUM CATION Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
9e37788c-b1bf-42ae-aac9-b60601606144Product name820260122
95250459-30e4-45c1-b08a-993044f49109Product name220250805
d9771140-739b-484b-ae64-b79528ff1211Product name320250801
efd58dcf-540a-4531-8766-e713129ca6f2Product name120250307
30b0ac6e-02aa-0e5c-0d8b-cffdf3a282b2Product name520250304
726062af-1135-4707-a1d7-57256991bbf9Product name220250226
1527ac37-808d-43be-a63e-74e1258dbe46Product name920250219
a21a21e5-f36d-4c1f-8918-def921b8f7e3Product name320250124
bed0530e-f939-4541-956b-6928a2f6404fProduct name120241008
cefa60e2-a5b5-493e-9c54-24735b7dc509Product name620240814
fb7ab793-2c12-4079-b100-a64f73bef25aProduct name420240712
362d7abb-94e6-4c60-9a58-266894157713Product name120231023
b0cbf770-6cc3-4aa4-9158-755110c2b9f7Product name220230717
dc7c5daa-021f-40dd-b00d-63982cb2067aProduct name120230426
9fcb7a91-de07-4f00-aabf-e4d6fda403d5Product name820230322
6bd95106-a412-1dad-b9cc-4cb74bfb27ceProduct name220230315
f1e0dc7e-7d61-4625-b6d9-4894927679d7Product name220211025
9badc7be-250a-44ab-aa36-926af3f02679Product name120210527
08ffbcbf-26df-b99c-1dab-64fc4cfae89fProduct name520200925
e4870509-7e28-6f92-f0be-dd3dd889a9cfProduct name520200810
0ec3537a-6c9b-432a-896c-b9ea8723049aProduct name920200701
6e9d4a47-c464-b93e-aebc-ad7bffc9c4cdProduct name220190619
444b3e50-f226-46ef-bfca-2e7035d140cdProduct name120190611
816b97af-edc5-4060-aff1-b814bdbcad50Product name120190415
7cda52fc-125f-421c-8fea-bc1974370c49Product name220180703
7916de40-e296-41f0-b811-6d0df1a33e2cProduct name920180627
cefa60e2-a5b5-493e-9c54-24735b7dc509Product name220171212
419aab54-5d5a-4146-9453-026d4a9991beProduct name220170525
26acd337-b838-40ac-bcbc-05c3b81c8712Product name120170323
08ffbcbf-26df-b99c-1dab-64fc4cfae89fProduct name220160823
d5e51f11-ad28-caa4-4b49-4143974782adProduct name120150831
290f523a-f9db-9774-b5a9-e1f908ac1782Product name120150828
0ca1d589-929b-4b33-bc5b-1d84abdafa6aProduct name120150324
fc363c46-397b-4476-ac0f-70e43e8e4592Product name120150324
89dac932-b90a-4410-9ab1-84c53e57de25Product name120150316
19c71a3d-ed9c-166b-a7e5-38c250c35631Product name120140508
5668b646-cd56-c3c7-bdea-3f6b1a8840dbProduct name120140508
597b1cfd-7b31-5048-62be-ca5cd740da2fProduct name120140508
684ea482-2e8b-14af-5664-b98f1e402036Product name120140508
810ab97e-f109-f41c-7c83-6a652a9cbf43Product name120140508
87711080-88eb-65c5-b2dd-bf99e700a372Product name120140508
8dbefedf-0a0d-a224-5a3c-66dc9e11c2ddProduct name120140508
b060cc1a-fe47-856b-0b77-4448b5963de8Product name120140508
c6b65c52-69c7-df49-550a-a50c137f6218Product name120140508
d723478e-ad4a-ec23-6bd7-cfe33e1e3840Product name120140508
ec2149b3-5c6d-5344-f757-c86411073075Product name120140508
ed912195-5da0-0f2f-6f4b-3ef17710cbe3Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
43386-060-19GaviLyte - CTM278.26 g in 1 BOTTLEPOWDER, FOR SOLUTION278.264

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
43386-060-19ML - Milliliter43386-0601d11e571-8e9f-4b71-a830-2e1e39fe2f0d12012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
POLYETHYLENE GLYCOL 3350ACTIVE INGREDIENTG2M7P15E5P1
POTASSIUM CHLORIDEACTIVE INGREDIENT660YQ98I101
SODIUM BICARBONATEACTIVE INGREDIENT8MDF5V39QO1
SODIUM CHLORIDEACTIVE INGREDIENT451W47IQ8X1
SODIUM SULFATE ANHYDROUSACTIVE INGREDIENT36KCS0R7501
CHLORIDE IONACTIVE MOIETYQ32ZN486981
POLYETHYLENE GLYCOL 3350ACTIVE MOIETYG2M7P15E5P1
POTASSIUM CATIONACTIVE MOIETY295O53K1521
SODIUM CATIONACTIVE MOIETYLYR4M0NH371
SULFATE IONACTIVE MOIETY7IS9N8KPMG1
ACACIAINACTIVE INGREDIENT5C5403N26O1
ALPHA-TOCOPHEROL, DL-INACTIVE INGREDIENT7QWA1RIO011
MALTODEXTRININACTIVE INGREDIENT7CVR7L4A2D1
SACCHARIN SODIUMINACTIVE INGREDIENTSB8ZUX40TY1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 13 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
43386-06043386-060-19

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 7 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 46 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DLOZENGE / ORAL175 mgExact identifier — unii+route
30 equally ranked IID candidates
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DTABLET / ORAL320 mgExact identifier — unii+route
30 equally ranked IID candidates
ALPHA-TOCOPHEROL, DL-.ALPHA.-TOCOPHEROL, DL-7QWA1RIO01TABLET, CHEWABLE / ORAL0.02 mgExact identifier — unii+route
12 equally ranked IID candidates
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DLOZENGE / ORAL175 mgExact identifier — unii+route
30 equally ranked IID candidates
SACCHARIN SODIUMSACCHARIN SODIUMSB8ZUX40TYPOWDER, FOR SOLUTION / ORAL199 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DTABLET, COATED / ORAL5.6 mgExact identifier — unii+route
30 equally ranked IID candidates
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DTABLET, EXTENDED RELEASE / ORAL3239 mgExact identifier — unii+route
30 equally ranked IID candidates
ALPHA-TOCOPHEROL, DL-.ALPHA.-TOCOPHEROL, DL-7QWA1RIO01SOLUTION / ORAL4 mgExact identifier — unii+route
12 equally ranked IID candidates
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DTABLET / ORAL320 mgExact identifier — unii+route
30 equally ranked IID candidates
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DTABLET, FILM COATED, EXTENDED RELEASE / ORALNAExact identifier — unii+route
30 equally ranked IID candidates
ALPHA-TOCOPHEROL, DL-.ALPHA.-TOCOPHEROL, DL-7QWA1RIO01TABLET / ORAL0.12 mgExact identifier — unii+route
12 equally ranked IID candidates
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DFILM, SOLUBLE / ORAL19 mgExact identifier — unii+route
30 equally ranked IID candidates
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DTABLET, ORALLY DISINTEGRATING / ORAL12 mgExact identifier — unii+route
30 equally ranked IID candidates
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DPOWDER, FOR SUSPENSION / ORAL8000 mgExact identifier — unii+route
30 equally ranked IID candidates
ALPHA-TOCOPHEROL, DL-.ALPHA.-TOCOPHEROL, DL-7QWA1RIO01POWDER, FOR SUSPENSION / ORALNAExact identifier — unii+route
12 equally ranked IID candidates
ALPHA-TOCOPHEROL, DL-.ALPHA.-TOCOPHEROL, DL-7QWA1RIO01TABLET / ORAL0.12 mgExact identifier — unii+route
12 equally ranked IID candidates
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DTABLET, ORALLY DISINTEGRATING / ORAL12 mgExact identifier — unii+route
30 equally ranked IID candidates
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DSUSPENSION / ORAL6040 mgExact identifier — unii+route
30 equally ranked IID candidates
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DTABLET, EXTENDED RELEASE / ORAL3239 mgExact identifier — unii+route
30 equally ranked IID candidates
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DSUSPENSION / ORAL6040 mgExact identifier — unii+route
30 equally ranked IID candidates
ACACIAACACIA5C5403N26OPOWDER, FOR SOLUTION / ORALNAExact identifier — unii+route+dosage form
2 equally ranked IID candidates
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DTABLET, CHEWABLE / ORAL292 mgExact identifier — unii+route
30 equally ranked IID candidates
ALPHA-TOCOPHEROL, DL-.ALPHA.-TOCOPHEROL, DL-7QWA1RIO01CAPSULE / ORAL90 mgExact identifier — unii+route
12 equally ranked IID candidates
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DPASTE / ORAL1050 mgExact identifier — unii+route
30 equally ranked IID candidates
ALPHA-TOCOPHEROL, DL-.ALPHA.-TOCOPHEROL, DL-7QWA1RIO01SUSPENSION / ORAL0.01 mg/1mlExact identifier — unii+route
12 equally ranked IID candidates
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DTABLET, FILM COATED, EXTENDED RELEASE / ORALNAExact identifier — unii+route
30 equally ranked IID candidates
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DTABLET, COATED / ORAL5.6 mgExact identifier — unii+route
30 equally ranked IID candidates
ALPHA-TOCOPHEROL, DL-.ALPHA.-TOCOPHEROL, DL-7QWA1RIO01CAPSULE / ORAL90 mgExact identifier — unii+route
12 equally ranked IID candidates
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DGRANULE, FOR SUSPENSION / ORAL952 mgExact identifier — unii+route
30 equally ranked IID candidates
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DPASTE / ORAL1050 mgExact identifier — unii+route
30 equally ranked IID candidates
ACACIAACACIA5C5403N26OPOWDER, FOR SOLUTION / ORALNAExact identifier — unii+route+dosage form
2 equally ranked IID candidates
ALPHA-TOCOPHEROL, DL-.ALPHA.-TOCOPHEROL, DL-7QWA1RIO01POWDER, FOR SUSPENSION / ORALNAExact identifier — unii+route
12 equally ranked IID candidates
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DFILM, SOLUBLE / ORAL19 mgExact identifier — unii+route
30 equally ranked IID candidates
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DCAPSULE / ORAL200 mgExact identifier — unii+route
30 equally ranked IID candidates
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DTABLET, CHEWABLE / ORAL292 mgExact identifier — unii+route
30 equally ranked IID candidates
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DTABLET, EFFERVESCENT / ORAL14404 mgExact identifier — unii+route
30 equally ranked IID candidates
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DCAPSULE / ORAL200 mgExact identifier — unii+route
30 equally ranked IID candidates
SACCHARIN SODIUMSACCHARIN SODIUMSB8ZUX40TYPOWDER, FOR SOLUTION / ORAL199 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DPOWDER, FOR SUSPENSION / ORAL8000 mgExact identifier — unii+route
30 equally ranked IID candidates
ALPHA-TOCOPHEROL, DL-.ALPHA.-TOCOPHEROL, DL-7QWA1RIO01SOLUTION / ORAL4 mgExact identifier — unii+route
12 equally ranked IID candidates
ALPHA-TOCOPHEROL, DL-.ALPHA.-TOCOPHEROL, DL-7QWA1RIO01SUSPENSION / ORAL0.01 mg/1mlExact identifier — unii+route
12 equally ranked IID candidates
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DSOLUTION / ORAL1451 mgExact identifier — unii+route
30 equally ranked IID candidates
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DGRANULE, FOR SUSPENSION / ORAL952 mgExact identifier — unii+route
30 equally ranked IID candidates
ALPHA-TOCOPHEROL, DL-.ALPHA.-TOCOPHEROL, DL-7QWA1RIO01TABLET, CHEWABLE / ORAL0.02 mgExact identifier — unii+route
12 equally ranked IID candidates
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DSOLUTION / ORAL1451 mgExact identifier — unii+route
30 equally ranked IID candidates
MALTODEXTRINMALTODEXTRIN7CVR7L4A2DTABLET, EFFERVESCENT / ORAL14404 mgExact identifier — unii+route
30 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A090186-001PEG 3350 AND ELECTROLYTESPOLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORALRS2009-06-01

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 44 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-10-15 13:18:302026-09A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORALRS2009-06-01c2088c7a36db…
2026-09-14 22:38:342026-08A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORALRS2009-06-0184e616aacf4f…
2026-08-18 06:07:402026-07A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORALRS2009-06-01caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORAL2009-06-01011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORAL2009-06-0131067a03dcf5…
2025-08-23 18:47 UTC2025-08A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORAL2009-06-016a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORAL2009-06-01fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORAL2009-06-01b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORAL2009-06-0103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORAL2009-06-012680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORAL2009-06-015bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORAL2009-06-01d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORAL2009-06-01d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORAL2009-06-0179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORAL2009-06-01301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORAL2009-06-011e350fbaab3a…
2024-05-31 18:47 UTC2024-05A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORAL2009-06-018072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORALAA2009-06-015c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORALAA2009-06-015d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORALAA2009-06-014b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORALAA2009-06-0174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORALAA2009-06-01bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORALAA2009-06-01782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORALAA2009-06-0187673890dc5c…
2021-03-12 10:30 UTC2021-03A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORALAA2009-06-015aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORALAA2009-06-018869cabd3fbd…
2020-11-12 02:37 UTC2020-11A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORALAA2009-06-01c0c555d07b60…
2019-12-14 00:12 UTC2019-12A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORALAA2009-06-013f01610625f2…
2019-09-15 20:21 UTC2019-09A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORALAA2009-06-01b00525d2431f…
2019-07-19 19:46 UTC2019-07A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORALAA2009-06-01ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORALAA2009-06-016a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORALAA2009-06-011c564ffb4f44…
2023-12-20 04:57 UTC2023-12A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORALAA2009-06-01ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORALAA2009-06-01a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORALAA2009-06-019b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORALAA2009-06-01a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORALAA2009-06-013f0d92c62455…
2023-05-13 08:27 UTC2023-05A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORALAA2009-06-01053a50430f4f…
2023-01-26 05:58 UTC2023-01A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORALAA2009-06-013bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A090186-001PEG 3350 AND ELECTROLYTES240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTFOR SOLUTION / ORALAA2009-06-013a93d1ddd44b…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A090186-001AA15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A090186-001AA15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A090186-001AA14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A090186-001AA174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A090186-001AA1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A090186-001AA1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A090186-001AA187673890dc5c…
2021-03-12 10:30 UTC2021-03A090186-001AA15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A090186-001AA18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A090186-001AA1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A090186-001AA13f01610625f2…
2019-09-15 20:21 UTC2019-09A090186-001AA1b00525d2431f…
2019-07-19 19:46 UTC2019-07A090186-001AA1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A090186-001AA16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A090186-001AA11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A090186-001AA1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A090186-001AA1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A090186-001AA19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A090186-001AA1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A090186-001AA13f0d92c62455…
2023-05-13 08:27 UTC2023-05A090186-001AA1053a50430f4f…
2023-01-26 05:58 UTC2023-01A090186-001AA13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A090186-001AA13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A090186-001AA1f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A090186-001AA1e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A090186-001AA1cb3db0bc1861…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
GaviLyte - C TMPOLYETHYLENE GLYCOL-3350 AND ELECTROLYTES WITH FLAVOR PACKLupin Pharmaceuticals,Inc.a8b15625-ca7c-4d57-9f36-3ac2a6d136652025-09-10Warnings, Adverse reactionsExact identifier
ndc (package): 43386-060-19
ndc (product): 43386-060
ndc11 (package): 43386006019
spl id: 5105b61a-4ca7-4096-9cd0-cf22f46ffaf8
spl set id: a8b15625-ca7c-4d57-9f36-3ac2a6d13665

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.